Destiny Pharma PLC Appointment of Nominated Adviser and Sole Broker (3547A)

TIDMDEST

RNS Number : 3547A

Destiny Pharma PLC

22 January 2024

Destiny Pharma plc

("Destiny Pharma" or "the Company")

Appointment of Nominated Adviser and Sole Broker

Brighton, United Kingdom - 22 January 2024 - Destiny Pharma (AIM: DEST), a clinical stage biotechnology company focused on the development and commercialisation of novel medicines to prevent and cure life threatening infections, is pleased to announce the appointment of Shore Capital and Corporate Limited as its Nominated Adviser and Shore Capital Stockbrokers Limited as its Sole Broker with immediate effect.

- END -

For further information, please contact:

Destiny Pharma plc

Chris Tovey, CEO

Shaun Claydon, CFO

[phone]

[e-mail]

Shore Capital (Nominated Adviser and Broker)

Daniel Bush / James Thomas / Lucy Bowden

[phone]

FTI Consulting (Financial PR)

Ben Atwell / Simon Conway / Michael Trace / Victoria Foster Mitchell

[phone]

[e-mail]

About Destiny Pharma

Destiny Pharma is an innovative, clinical-stage biotechnology company focused on the development and commercialisation of novel medicines that can prevent life-threatening infections. The company's drug development pipeline includes two late stage assets NTCD-M3, a microbiome-based biotherapeutic for the prevention of C. difficile infection (CDI) recurrence which is the leading cause of hospital acquired infection in the US, and XF-73 nasal gel, a proprietary drug targeting the prevention of post-surgical staphylococcal hospital infections including MRSA.

For further information on the company, please visit www.destinypharma.com

Existing Board - AIM Rule 17 Disclosures

The Group announces the following information is being disclosed pursuant to Rule 17 and Schedule Two Paragraph (g) of the AIM Rules for Companies:

Sir Nigel Rudd - Chairman

Sir Nigel Rudd is a director of Loch Lomond Members Golf Club Limited. He was appointed on 29 November 2010; as such this was a current directorship at the date of the Company's announcement entitled "Appointment of new Chairman" dated 25 July 2023.

Christopher Tovey - Chief Executive Officer

Christopher Tovey was a former director of GW Pharma (Germany) GmbH and GW Pharma (France) SARL within 5 years of the date of the Company's announcement entitled "Board changes including appointment of new CEO" dated 19 July 2023.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

APPBLGDBCUBDGSC

(END) Dow Jones Newswires

January 22, 2024 02:00 ET (07:00 GMT)